Hologic Inc

Hologic Inc Stock Forecast & Price Prediction

Live Hologic Inc Stock (HOLX) Price
$80.24

19

Ratings

  • Buy 14
  • Hold 5
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$80.24

P/E Ratio

27.17

Volume Traded Today

$1.2M

Dividend

Dividends not available for HOLX

52 Week High/low

84.67/64.02

Hologic Inc Market Cap

$18.49B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $HOLX ๐Ÿ›‘

Before you buy HOLX you'll want to see this list of ten stocks that have huge potential. Want to see if HOLX made the cut? Enter your email below

HOLX Summary

From what 19 stock analysts predict, the share price for Hologic Inc (HOLX) might increase by 9.93% in the next year. This is based on a 12-month average estimation for HOLX. Price targets go from $82 to $96. The majority of stock analysts believe HOLX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

HOLX Analyst Ratings

Hologic Inc has a total of 19 Wall St Analyst ratings. There are 14 buy ratings, 5 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Hologic Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

HOLX stock forecast by analyst

These are the latest 20 analyst ratings of HOLX.

Analyst/Firm

Rating

Price Target

Change

Date

Vijay Kumar
Evercore ISI Group

In-Line

$82

Maintains

Oct 1, 2024
Patrick Donnelly
Citigroup

Neutral

$85

Downgrade

Oct 1, 2024
Mike Matson
Needham

Buy

$90

Reiterates

Sep 17, 2024
Conor McNamara
RBC Capital

Sector Perform

$82

Reiterates

Aug 16, 2024
Mason Carrico
Stephens & Co.

Overweight

$92

Reiterates

Jul 30, 2024
Casey Woodring
JP Morgan

Overweight

$95

Maintains

Jul 30, 2024
Vijay Kumar
Evercore ISI Group

In-Line

$78

Maintains

Jul 30, 2024
Conor McNamara
RBC Capital

Sector Perform

$82

Maintains

Jul 30, 2024
Mike Matson
Needham

Buy

$90

Reiterates

Jul 30, 2024
Vijay Kumar
Evercore ISI Group

In-Line

$76

Maintains

Jul 2, 2024
Mason Carrico
Stephens & Co.

Overweight

$87

Initiates

Jun 27, 2024
David Toung
Argus Research

Buy

$95

Maintains

May 9, 2024
Casey Woodring
JP Morgan

Overweight

$91

Maintains

May 3, 2024
Mike Matson
Needham

Buy

$90

Reiterates

May 3, 2024
Mike Matson
Needham

Buy

$90

Reiterates

Apr 10, 2024
Vijay Kumar
Evercore ISI Group

In-Line

$78

Maintains

Apr 4, 2024
Patrick Donnelly
Citigroup

Buy

$95

Upgrade

Apr 3, 2024
Mike Matson
Needham

Buy

$90

Maintains

Feb 2, 2024
Elizabeth Garcia
UBS

Neutral

$79

Maintains

Feb 2, 2024
Andrew Cooper
Raymond James

Outperform

$88

Maintains

Feb 2, 2024

HOLX Company Information

What They Do: Develops medical products for women's health.

Business Model: The company generates revenue through the development, manufacturing, and supply of various diagnostics products, medical imaging systems, and surgical products specifically designed for women's health. It operates across four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health, utilizing a combination of direct sales and independent distributors to reach its customer base.

Other Information: Hologic offers a diverse range of products, including molecular diagnostic assays for various infections, advanced breast cancer care solutions, and minimally invasive surgical systems. The company has a strong focus on early detection and treatment, providing critical tools for healthcare providers. Founded in 1985 and based in Marlborough, Massachusetts, Hologic continues to innovate in the women's health sector.
HOLX
Hologic Inc (HOLX)

When did it IPO

1990

Staff Count

6,990

Country

United States

Sector/Industry

Healthcare/Medical Instruments & Supplies

CEO

Mr. Stephen P. MacMillan

Market Cap

$18.49B

Hologic Inc (HOLX) Financial Data

In 2023, HOLX generated $4.03B in revenue, which was a decrease of -17.12% from the previous year. This can be seen as a signal that HOLX's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$3.78B

Revenue From 2021

$5.63B

49.14 %
From Previous Year

Revenue From 2022

$4.86B

-13.66 %
From Previous Year

Revenue From 2023

$4.03B

-17.12 %
From Previous Year
  • Revenue TTM $3.99B
  • Operating Margin TTM 26.1%
  • Gross profit TTM $2.07B
  • Return on assets TTM 6.4%
  • Return on equity TTM 13.8%
  • Profit Margin 17.6%
  • Book Value Per Share 21.34%
  • Market capitalisation $18.49B
  • Revenue for 2021 $5.63B
  • Revenue for 2022 $4.86B
  • Revenue for 2023 $4.03B
  • EPS this year (TTM) $2.93

Hologic Inc (HOLX) Latest News

News Image

Mon, 30 Sep 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Hologic (HOLX) is attracting attention from Zacks.com users, indicating potential interest in the stock's future performance and investment prospects.

Why It Matters - Increased interest in Hologic (HOLX) suggests potential volatility or upcoming developments, signaling investors to monitor the stock for possible investment opportunities or risks.

News Image

Mon, 30 Sep 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - Hologic launched the #BustTheMyth campaign to debunk breast cancer myths and empower women during Breast Cancer Awareness Month.

Why It Matters - Hologic's campaign may enhance brand reputation and drive product demand, positively impacting sales and stock performance, particularly in the healthcare sector.

News Image

Fri, 27 Sep 2024

Sentiment - NEUTRAL

Source - Zacks Investment Research

Summary - Hologic shows strong potential in Molecular Diagnostics, but may face challenges due to macroeconomic uncertainties affecting its operations.

Why It Matters - Hologic's growth potential in Molecular Diagnostics may drive future profits, but macroeconomic uncertainties could impact revenue stability and overall investment risk.

News Image

Fri, 27 Sep 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Hologic expands its breast health product line to include imaging, biopsy, and surgery, enhancing its comprehensive breast cancer care offerings.

Why It Matters - Hologic's expanded product range enhances its market position in breast cancer care, potentially increasing revenue streams and attracting investor interest in its growth prospects.

News Image

Tue, 24 Sep 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Zacks Premium offers Style Scores to help value, growth, and momentum investors identify strong stocks more easily.

Why It Matters - The Zacks Style Scores enhance stock selection across investment strategies, potentially leading to better returns and informed investment decisions.

News Image

Fri, 20 Sep 2024

Sentiment - NEUTRAL

Source - Zacks Investment Research

Summary - Hologic (HOLX) closed at $81.39, reflecting a decline of 1.23% from the previous trading day.

Why It Matters - Hologic's stock decline signals potential concerns about its performance or market perception, which may affect investor sentiment and future trading decisions.

...

HOLX Frequently asked questions

The highest forecasted price for HOLX is $96 from at .

The lowest forecasted price for HOLX is $82 from Puneet Souda from SVB Leerink

The HOLX analyst ratings consensus are 14 buy ratings, 5 hold ratings, and 0 sell ratings.